Antihistamines in the treatment of allergic rhinitis in children

A.E. Abaturov, E.L. Krivusha, V.L. Babich


The review of the literature provides current information about the clinical efficacy, safety and tolerability of the classic second-generation H1-antihistamine, desloratadine, in the treatment of allergic rhinitis in children. For writing the article, we used such databases, as Scopus, Web of Science, MedLine, PubMed, Google Scholar. A brief description of the pharmacokinetics and pharmacodynamics of desloratadine, which is a potent and selective inverse agonist for H1-receptors, with the longest half-life, does not penetrate the blood-brain barrier and does not have a sedative effect. Attention is focused on the ability of desloratadine not only to effectively inhibit histamine-associated clinical manifestations of allergic rhinitis, but also to inhibit the activity of the inflammatory process by decreasing the activity of transcription nuclear factor kappa B. Scientific studies demonstrate a high efficacy of desloratadine in the relief of clinical manifestations of allergic rhinitis in children and a good safety profile during its use.


H1-antihistamines; desloratadine; allergic rhinitis; children; review


Abaturov AE, Borisova TP. The optimal choice of antihistamine medicine in allergic diseases in children. Zdorovʹe rebenka. 2017;12(1):81-89. (in Russian).

Vishneva YeA. Application of nonsedative antihistamins at allergic pathology in children. Desloratadine. Pediatricheskaya Farmakologiya. 2009;6(1):70-74. (in Russian).

Goriachkina LA. Modern antihistamines in the treatment of allergic diseases. RMJ. 2001;9(21):945-950. (in Russian).

Gushchin IS. Prospects for improving the antiallergic effect of H1-antihistamines. Lechaschi Vrach. 2009;(5):64-67. (in Russian).

Emelyanov AV. Clinical use of H1-antihistamines. Meditsinskiy Sovet. 2016;(4):74-81. (in Russian).

Ilyna NI, Pavlova KS. Antihistamines, anti-inflammatory and anti-allergic properties of desloratadine. Consilium Medicum. 2015;17(3):79-83. (in Russian).

Karaulov AV. Antihistamines in treatment of allergic diseases in children: focus on desloratadin in allergic rinse. Pharmateca. 2012;(Suppl 3):64-67. (in Russian).

Leonova MV, Dvornikov AS, Skripkina PA, Minkina OV, Gaidina TA. Antihistamines in treatment of chronic urticaria. Review of modern recommendations. 2016;(19):48-57. (in Russian).

Leonova MV. Modern antihistamines: choice in abundance of drugs. Pharmateca. 2011;(10):26-31. (in Russian).

Petrov VI, Maljuzhinskaya NV, Shishimorov IN. Clinical efficiency of desloratadine therapy in children with persistent form of allergic rhinitis and its effect on bronchial asthma symptoms. Saratovskij naučno-medicinskij žurnal. 2010;6(1):073-076. (in Russian).

Prosekova EV, Turyanskaya AI, Netesova SYu, Sabynych VA. Efficiency of antihistamine medications for treatment of persistent allergic rhinitis in primary school children: clinical and immunological aspects. Russian Allergology Journal. 2016;(1):57-62. (in Russian).

Saigitov RT. Desloratadine in treatment of allergic rhinitis: results of randomized, placebo-controlled trial. Voprosy Sovremennoi Pediatrii. 2008;7(1):82-91. (in Russian).

Svistushkin VM, Starostina SV. Modern approaches to systemic therapy of allergic rhinitis. RMJ. 2016;24(4):240-244. (in Russian).

Таtaourshikova NS. Desloratadine is a modern effective treatment for allergic rhinitis. Pharmateca. 2013;(263):66-68. (in Russian).

Umanets TR. Bronchial asthma and allergic rhinitis: ways to optimize the compliance and effectiveness of treatment. Astma ta alergija. 2015;(1):61-64. (in Russian).

Fajzullina RM, Guseva YeD. Efficacy of desloratadine treatment of children with allergic rhinitis. Voprosy Sovremennoi Pediatrii. 2015;14(5):597-599. (in Russian).

Agrawal DK. Anti-inflammatory properties of desloratadine. Clin Exp Allergy. 2004 Sep;34(9):1342-8. doi: 10.1111/j.1365-2222.2004.02026.x.

Anthes JC, Gilchrest H, Richard C, et al. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur J Pharmacol. 2002 Aug 9;449(3):229-37. doi: 10.1016/S0014-2999(02)02049-6.

Bakker RA, Schoonus SB, Smit MJ, Timmerman H, Leurs R. Histamine H(1)-receptor activation of nuclear factor-kappa B: roles for G beta gamma- and G alpha(q/11)-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol. 2001 Nov;60(5):1133-42. doi: 10.1124/mol.60.5.1133.

Barecki ME, Casciano CN, Johnson WW, Clement RP. In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug Metab Dispos. 2001 Sep;29(9):1173-5. PMID: 11502723.

Berger WE. The safety and efficacy of desloratadine for the management of allergic disease. Drug Saf. 2005;28(12):1101-18. PMID: 16329713.

Bloom M, Staudinger H, Herron J. Safety of desloratadine syrup in children. Curr Med Res Opin. 2004 Dec;20(12):1959-65. doi: 10.1185/030079904X14148.

Bocşan CI, Bujor AI, Miron N, Vesa ŞC, Deleanu D, Buzoianu AD. In vivo anti-inflammatory effect of H1 antihistamines in allergic rhinitis: a randomized clinical trial. Balkan Med J. 2015 Oct;32(4):352-8. doi: 10.5152/balkanmedj.2015.15884.

Bousquet J, Zuberbier T, Canonica GW, Fokkens WJ, Gopalan G, Shekar T. Randomized controlled trial of desloratadine for persistent allergic rhinitis: correlations between symptom improvement and quality of life. Allergy Asthma Proc. 2013 May-Jun;34(3):274-82. doi: 10.2500/aap.2013.34.3668.

Bousquet J, Bindslev-Jensen C, Canonica GW, et al. The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine. Allergy. 2004;59(Suppl 77):4-16. doi: 10.1111/j.1398-9995.2004.00577.x.

Bousquet J, Van Cauwenberge P, Bachert C, et al. Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy. 2003 Mar;58(3):192-7. doi: 10.1034/j.1398-9995.2003.00054.x.

Bozek A. Pharmacological management of allergic rhinitis in the elderly. Drugs Aging. 2017 Jan;34(1):21-28. doi: 10.1007/s40266-016-0425-7.

Brożek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017 Oct;140(4):950-958. doi: 10.1016/j.jaci.2017.03.050.

Camelo-Nunes IC. New antihistamines: a critical view. J Pediatr (Rio J). 2006 Nov;82(5 Suppl):S173-80. doi: 10.2223/JPED.1552.

Campo P, Salas M, Blanca-López N, Rndoón C. Local Allergic Rhinitis. Immunol Allergy Clin North Am. 2016 May;36(2):321-32. doi: 10.1016/j.iac.2015.12.008.

Canonica GW, Blaiss M. Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence. World Allergy Organ J. 2011 Feb;4(2):47-53. doi: 10.1097/WOX.0b013e3182093e19.

Chen M, Xu S, Zhou P, He G, Jie Q, Wu Y. Desloratadine citrate disodium injection, a potent histamine H(1) receptor antagonist, inhibits chemokine production in ovalbumin-induced allergic rhinitis guinea pig model and histamine-induced human nasal epithelial cells via inhibiting the ERK1/2 and NF-kappa B signal cascades. Eur J Pharmacol. 2015 Nov 15;767:98-107. doi: 10.1016/j.ejphar.2015.10.014.

Church DS, Church MK. Pharmacology of antihistamines. World Allergy Organ J. 2011 Mar;4(3 Suppl):S22-7. doi: 10.1097/WOX.0b013e3181f385d9.

Church MK. Allergy, Histamine and Antihistamines. Handb Exp Pharmacol. 2017;241:321-331. doi: 10.1007/164_2016_85.

Church MK, Church DS. Pharmacology of antihistamines. Indian J Dermatol. 2013 May;58(3):219-24. doi: 10.4103/0019-5154.110832.

Church MK, Maurer M. Antihistamines. Chem Immunol Allergy. 2014;100:302-10. doi: 10.1159/000359963.

Ciebiada M, Barylski M, Gorska Ciebiada M. Nasal eosinophilia and serum soluble intercellular adhesion molecule 1 in patients with allergic rhinitis treated with montelukast alone or in combination with desloratadine or levocetirizine. Am J Rhinol Allergy. 2013 Mar-Apr;27(2):e58-62. doi: 10.2500/ajra.2013.27.3881.

Cyr MM, Hayes LM, Crawford L, Baatjes AJ, Keith PK, Denburg JA. The effect of desloratadine on eosinophil/basophil progenitors and other inflammatory markers in seasonal allergic rhinitis: a placebo-controlled randomized study. Int Arch Allergy Immunol. 2005 Nov;138(3):209-16. doi: 10.1159/000088721.

Di Sciascio MB, Vianale G, Verna N, et al. Eosinophil recruiting chemokines are down-regulated in peripheral blood mononuclear cells of allergic patients treated with deflazacort or desloratadine. Int J Immunopathol Pharmacol. 2007 Oct-Dec;20(4):745-51. doi: 10.1177/039463200702000410.

Dizdar EA, Sekerel BE, Keskin O, et al. The effect of regular versus on-demand desloratadine treatment in children with allergic rhinitis. Int J Pediatr Otorhinolaryngol. 2007 Jun;71(6):843-9. doi: 10.1016/j.ijporl.2007.02.003.

Fischer MJ, Paulussen JJ, de Mol NJ, Janssen LH. Dual effect of the anti-allergic astemizole on Ca2+ fluxes in rat basophilic leukemia (RBL-2H3) cells: release of Ca2+ from intracellular stores and inhibition of Ca2+ release-activated Ca2+ influx. Biochem Pharmacol. 1998 Apr 15;55(8):1255-62. doi: 10.1016/S0006-2952(97)00600-X.

Fitzsimons R, van der Poel LA, Thornhill W, du Toit G, Shah N, Brough HA. Antihistamine use in children. Arch Dis Child Educ Pract Ed. 2015 Jun;100(3):122-31. doi: 10.1136/archdischild-2013-304446.

Gauvreau GM, El-Gammal AI, O'Byrne PM. Allergen-induced airway responses. Eur Respir J. 2015 Sep;46(3):819-31. doi: 10.1183/13993003.00536-2015.

Gillman S, Gillard M, Benedetti MS. The concept of substitution of receptors as a predictor of the clinical effectiveness of the drug: a comparative analysis of second-generation H1-receptor blockers. Sovremennaya Pediatriya. 2015;(69):29-35. (in Russian).

González-Núñez V, Valero A, Mullol J. Safety evaluation of desloratadine in allergic rhinitis. Expert Opin Drug Saf. 2013 May;12(3):445-453. doi: 10.1517/14740338.2013.788148.

Grützkau A, Smorodchenko A, Lippert U, Kirchhof L, Artuc M, Henz BM. LAMP-1 and LAMP-2, but not LAMP-3, are reliable markers for activation-induced secretion of human mast cells. Cytometry A. 2004 Sep;61(1):62-68. doi: 10.1002/cyto.a.20068.

Incorvaia C, Fuiano N, Martignago I, Gritti BL, Ridolo E. Local allergic rhinitis: evolution of concepts. Clin Transl Allergy. 2017 Nov 2;7:38. doi: 10.1186/s13601-017-0174-7.

Kashiwakura JI, Ando T, Kawakami T. Role of Histamine-releasing Factor in Allergic Inflammatory Reactions. Yakugaku Zasshi. 2017;137(5):517-521. doi: 10.1248/yakushi.16-00239-3. (in Japanese).

Kazmi F, Yerino P, Barbara JE, Parkinson A. Further Characterization of the Metabolism of Desloratadine and Its Cytochrome P450 and UDP-glucuronosyltransferase Inhibition Potential: Identification of Desloratadine as a Relatively Selective UGT2B10 Inhibitor. Drug Metab Dispos. 2015 Sep;43(9):1294-302. doi: 10.1124/dmd.115.065011.

Kim K, Sussman G, Hébert J, Lumry W, Lutsky B, Gates D. Desloratadine therapy for symptoms associated with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2006 Mar;96(3):460-5. doi: 10.1016/S1081-1206(10)60914-3.

Kowalski ML, Lewandowska A, Wozniak J, Makowska J, Jankowski A, DuBuske L. Inhibition of nasal polyp mast cell and eosinophil activation by desloratadine. Allergy. 2005 Jan;60(1):80-5. doi: 10.1111/j.1398-9995.2005.00642.x.

Layton D, Wilton L, Shakir SA. Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79. doi: 10.2165/00002018-200932020-00009.

Lee KS, Yu J, Shim D, et al. Local Immune Responses in Children and Adults with Allergic and Nonallergic Rhinitis. PLoS One. 2016 Jun 9;11(6):e0156979. doi: 10.1371/journal.pone.0156979.

Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002 Apr;32(4):489-98. doi: 10.1046/j.0954-7894.2002.01314.x.

Lippert U, Möller A, Welker P, Artuc M, Henz BM. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol. 2000 Apr;9(2):118-24. doi: 10.1034/j.1600-0625.2000.009002118.x.

London NR Jr, Tharakan A, Ramanathan MJr. The role of innate immunity and aeroallergens in chronic rhinosinusitis. Adv Otorhinolaryngol. 2016;79:69-77. doi: 10.1159/000445132.

Matsubara M, Tamura T, Ohmori K, Hasegawa K. Histamine H1 receptor antagonist blocks histamine-induced proinflammatory cytokine production through inhibition of Ca2+-dependent protein kinase C, Raf/MEK/ERK and IKK/I kappa B/NF-kappa B signal cascades. Biochem Pharmacol. 2005 Feb 1;69(3):433-49. doi: 10.1016/j.bcp.2004.10.006.

Miyake K, Karasuyama H. Emerging roles of basophils in allergic inflammation. Allergol Int. 2017 Jul;66(3):382-391. doi: 10.1016/j.alit.2017.04.007.

Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol. 2004 Aug;18(4):399-411. doi: 10.1111/j.1472-8206.2004.00254.x.

Monczor F, Fernandez N, Fitzsimons CP, Shayo C, Davio C. Antihistaminergics and inverse agonism: potential therapeutic applications. Eur J Pharmacol. 2013 Sep 5;715(1-3):26-32. doi: 10.1016/j.ejphar.2013.06.027.

Moneret-Vautrin DA, de Chillou C, Codreanu A. Long QT syndrome in a patient with allergic rhinoconjunctivitis and auto-immune diabetes: focus on the choice of anti-H1 drugs. Eur Ann Allergy Clin Immunol. 2006 Dec;38(10):347-50. PMID: 17274518.

Mouly S, Lloret-Linares C, Sellier PO, Sene D, Bergmann JF. Is the clinical relevance of drug-food and drug-herb interactions limited to grapefruit juice and Saint-John's Wort? Pharmacol Res. 2017 Apr;118:82-92. doi: 10.1016/j.phrs.2016.09.038.

Mullol J, de Borja Callejas F, Martínez-Antón MA, et al. Mometasone and desloratadine additive effect on eosinophil survival and cytokine secretion from epithelial cells. Respir Res. 2011 Feb 27;12:23. doi: 10.1186/1465-9921-12-23.

Numminen J. Allergic rhinitis. Duodecim. 2017;133(5):473-8. PMID: 29205994.

Panula P, Cahzot PL, Cowart M, et al. International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors. Pharmacol Rev. 2015 Jul;67(3):601-55. doi: 10.1124/pr.114.010249.

Paśko P, Rodacki T, Domagała-Rodacka R, Palimonka K, Marcinkowska M, Owczarek D. Second generation H1 - antihistamines interaction with food and alcohol-A systematic review. Biomed Pharmacother. 2017 Sep;93:27-39. doi: 10.1016/j.biopha.2017.06.008.

Platt M. Pharmacotherapy for allergic rhinitis. Int Forum Allergy Rhinol. 2014 Sep;4 (Suppl 2):S35-40. doi: 10.1002/alr.21381.

Rondón C, Campo P, Togias A, et al. Local allergic rhinitis: concept, pathophysiology, and management. J Allergy Clin Immunol. 2012 Jun;129(6):1460-7. doi: 10.1016/j.jaci.2012.02.032.

Rondón C, Romero JJ, López S, et al. Local IgE production and positive nasal provocation test in patients with persistent nonallergic rhinitis. J Allergy Clin Immunol. 2007 Apr;119(4):899-905. doi: 10.1016/j.jaci.2007.01.006.

Rosenwasser LJ. Current understanding of the pathophysiology of allergic rhinitis. Immunol Allergy Clin North Am. 2011 Aug;31(3):433-9. doi: 10.1016/j.iac.2011.05.009.

Sakano E, Sarinho ESC, Cruz AA, et al. IV Brazilian Consensus on Rhinitis - an update on allergic rhinitis. Braz J Otorhinolaryngol. 2017 Nov 2. pii: S1808-8694(17)30187-8. doi: 10.1016/j.bjorl.2017.10.006.

Schroeder JT, Schleimer RP, Lichtenstein LM, Kreutner W. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy. 2001 Sep;31(9):1369-77. doi: 10.1046/j.1365-2222.2001.01130.x.

Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis executive summary. Otolaryngol Head Neck Surg. 2015 Feb;152(2):197-206. doi: 10.1177/0194599814562166.

Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: Allergic rhinitis. Otolaryngol Head Neck Surg. 2015 Feb;152(1 Suppl):S1-43. doi: 10.1177/0194599814561600.

Simons FE, Prenner BM, Finn A Jr; Desloratadine Study Group. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2003 Mar;111(3):617-22. PMID: 12642846.

Simons FE, Simons KJ. H1 antihistamines: current status and future directions. World Allergy Organ J. 2008 Sep;1(9):145-55. doi: 10.1097/WOX.0b013e318186fb3a.

Suárez-Castañón C, Modroño-Riaño G, Solís-Sánchez G. Allergol Immunopathol (Madr). 2017 Sep-Oct;45(5):506-507. doi: 10.1016/j.aller.2016.10.012.

Tassinari P, Suárez NR, Centeno J, et al. Desloratadine therapy improves allergic rhinitis symptoms in latin american children aged 6 to 12 years. World Allergy Organ J. 2009 Apr;2(4):42-8. doi: 10.1097/WOX.0b013e31819cdfdb.

Varshney J, Varshney H. Allergic Rhinitis: an Overview. Indian J Otolaryngol Head Neck Surg. 2015 Jun;67(2):143-9. doi: 10.1007/s12070-015-0828-5.

Wandalsen GF, Miranda C, Ensina LF, et al. Association between desloratadine and prednisolone in the treatment of children with acute symptoms of allergic rhinitis: a double-blind, randomized and controlled clinical trial. Braz J Otorhinolaryngol. 2017 Nov-Dec;83(6):633-639. doi: 10.1016/j.bjorl.2016.08.009.

Wang XY, Lim-Jurado M, Prepageran N, Tantilipikorn P, Wang de Y. Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine. Ther Clin Risk Manag. 2016 Apr 13;12:585-97. doi: 10.2147/TCRM.S105189.

Weller K, Maurer M. Desloratadine inhibits human skin mast cell activation and histamine release. J Invest Dermatol. 2009 Nov;129(11):2723-6. doi: 10.1038/jid.2009.134.

Wilken JA, Daly AF, Sullivan CL, Kim H. Desloratadine for allergic rhinitis. Expert Rev Clin Immunol. 2006 Mar;2(2):209-24. doi: 10.1586/1744666X.2.2.209.

Xu Y, Zhang J, Wang J. The efficacy and safety of selective H1-antihistamine versus leukotriene receptor antagonist for seasonal allergic rhinitis: a meta-analysis. PLoS One. 2014 Nov 10;9(11):e112815. doi: 10.1371/journal.pone.0112815.

Yamanishi Y, Miyake K, Iki M, Tsutsui H, Karasuyama H. Recent advances in understanding basophil-mediated Th2 immune responses. Immunol Rev. 2017 Jul;278(1):237-245. doi: 10.1111/imr.12548.

Yuan X, Ghosh A, Jie Q, He G, Wu Y. Effects of desloratadine citrate disodium injection on rat models of ovalbumin-induced allergic rhinitis: involvement of T-cell responses modulation. Int Forum Allergy Rhinol. 2015 Dec;5(12):1170-6. doi: 10.1002/alr.21594.

Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: management of urticarial. Allergy. 2006 Mar;61(3):321-31. doi: 10.1111/j.1398-9995.2005.00962.x.

Copyright (c) 2020 A.E. Abaturov, E.L. Krivusha, V.L. Babich

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2020


   Seo анализ сайта